HOME >> BIOLOGY >> NEWS
UNC HIV-AIDS screening, prevention method could become national model for cutting illness

also are tested individually through what's called polymerase chain reaction (PCR).

"So far, we have tested about 50,000 patients, and the most important thing we have observed is that a significant number of very contagious infections are right now being missed by routine antibody testing," Pilcher said.

In addition, he said, patients can potentially benefit themselves if doctors know to start them quickly and aggressively on anti-retroviral treatment. Several preliminary studies have shown recently that early treatment may improve their long-term prognosis.

The detection of acute HIV infections can have important public health benefits as well, Pilcher said.

"Having the means to distinguish newly infected from long-ago infected individuals can reveal actual populations getting infected in something like real time and can provide guidance and feedback to the state's HIV prevention efforts."

Other medical scientists had suggested that the pooling technique could uncover individual new acute HIV cases among large groups of at-risk people, but the UNC investigators and their colleagues were the first to try the idea.

Other states have expressed interest in conducting similar screening. According to the JAMA article, the U.S. Centers for Disease Control and Prevention will award grants before long to study the feasibility of wider RNA screening across the country.


'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
29-May-2003


Page: 1 2 3

Related biology news :

1. Researchers report definitive evidence that HIV-AIDS is not from oral polio vaccine
2. DNA biochip may lead to fast genetic screening, more effective drugs
3. Leader in cancer treatment and prevention research honored
4. OHSU researchers discover possible method for early detection, prevention of premature birth
5. Colleagues to recognize research leadership in cancer detection, prevention and treatment
6. Rutgers cancer prevention expert calls for FDA action to reduce colon cancer and osteoporosis
7. Indoor mold, building dampness linked to respiratory problems and require better prevention
8. Insight into transplant rejection might lead to novel prevention therapies
9. Scientists making advances in cancer prevention, detection and treatment to receive awards
10. Oral drug showing promise for breast cancer prevention in a mouse model
11. Novel approaches to current cellular therapies continue progress toward disease prevention

Post Your Comments:
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
(Date:3/12/2015)... , March 12, 2015 The mascots of ... Children,s Hospital, part of Wake Forest Baptist Medical Center. ... for the 2015 ACC Men,s Basketball Tournament. Young patients ... them and getting their autographs. Brenner Children,s ... It is the only children,s hospital in northwest ...
(Date:3/10/2015)... 2015  Continuing its 167-year history of offering the ... The Eye Scanning Password Authenticator , a device ... secure websites or sensitive data. Employing the ... borders, the device has a small camera that scans ... iris, converting them into an encrypted ID that cannot ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
(Date:3/25/2015)... 25, 2015  S&P Capital IQ (MHFI) announced ... Report coverage on Abattis Bioceuticals Corp . ... is a specialty biotechnology company with capabilities through ... marketing proprietary ingredients, bio-similar compounds, patented equipment and ... North America . The company seeks to ...
(Date:3/25/2015)... , CAMBRIDGE, Mass. and ... NextCODE, which provides comprehensive capabilities for using the genome to ... on their publication of the largest studies of whole-genome data ... online in Nature Genetics – are ... sequence variation, authored by a team of deCODE scientists led ...
(Date:3/25/2015)... CA (PRWEB) March 25, 2015 ... for Novel Mechanism of Action in Neuromuscular Diseases ... 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced the ... skeletal muscle troponin activator tirasemtiv in the journal ... Phase IIa “Evidence of Effect” or hypothesis-generating clinical ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5Landmark deCODE Studies Demonstrate the Power of Truly Big Genomics for Improving Medicine Worldwide 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
Cached News: